Compare Abbott Laboratories (ABT) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Booking Holdings Inc — how do they compare? Abbott Laboratories trades at $95.41 (market cap $166.94B), while Booking Holdings Inc trades at $174.57 (market cap $140.99B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | BKNG | |
|---|---|---|
Market Cap | $166.94B | $140.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $231.02 |
52-Week Low | $82.57 | $154.13 |
Enterprise Value | $193.69B | $143.91B |
Dividend Yield | 2.63% | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Booking Holdings (BKNG) trades at $181.95, down 1.41% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with 2025 revenue of $26.92B and net income margin of 22.23%, though Q2 2026 earnings are pending. Analyst consensus remains strongly positive with 64% buy ratings and a $225 price target, representing 24% upside potential from current levels.
BKNG presents a compelling investment case with robust cash flow generation ($9.4B operating cash flow in 2025) and dominant market position, though risks include high debt levels (64% debt-to-asset ratio) and AI disruption concerns. The stock's current valuation at 23.87 P/E appears reasonable given growth prospects, with upcoming Q2 earnings on August 4 serving as the next key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
